discover our approach
Activating the cancer-immunity cycle
For an anticancer immune response that may lead to the effective killing of cancer cells, key processes that constitute the “cancer-immunity cycle” must be stimulated (activated, engaged, and promoted).1
Research and development at Nektar Therapeutics focuses on pathways that may drive an antitumor immune response.2-5
APC=antigen-presenting cell; CAR-T=chimeric antigen receptor T-cell therapy; CIs=checkpoint inhibitors; mAbs=monoclonal antibodies.
References: 1. Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity. 2013;39(1):1-10. 2. Charych D, Khalili S, Dixit V, et al. Modeling the receptor pharmacology, pharmacokinetics, and pharmacodynamics of NKTR-214, a kinetically-controlled interleukin-2 (IL2) receptor agonist for cancer immunotherapy. PLoS One. 2017;12(7):e0179431. doi:10.1016/j.immuni.2013.07.012. 3. Robinson TO, Schluns KS. The potential and promise of IL-15 in immuno-oncogenic therapies. Immunol Lett. 2017;190:159-168. 4. Adams S. Toll-like receptor agonists in cancer therapy. Immunotherapy. 2009;1(6):949-964. doi:10.2217/imt.09.70. 5. Data on File. Nektar Therapeutics.